279 abstracts found.



POSNOC – Positive Sentinel Node: Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy(ISRCTN54765244, Clinicaltrials.gov NCT02401685)

Year:

Session type:

Theme:

Amit Goyal1
1Royal Derby Hospital

Developing new paradigms for overcoming drug resistance in cancer using novel humanised mouse models

Year:

Session type:

Theme:

Colin Henderson1,Yury Kapelyukh1,Kenneth MacLeod2,De Lin1,Aileen McLaren1,Roland Wolf1
1University of Dundee,2Concept Life Sciences

Structure-based virtual screening identifies pranlukast as a CD49f antagonist that reduces stemness in MDA-MB-231 breast cancer cells

Year:

Session type:

Theme:

Marco Velasco-Velazquez1,Inés Velázquez-Quesada1,Angel Ruiz-Moreno1,Diana Casique-Aguirre1,Charmina Aguirre-Alvarado1,Fabiola Cortés-Mendoza1,Marisol de la Fuente-Granada1,Mayra Pérez-Tapia2,Aliesha Gonzalez-Arenas1,Aldo Segura-Cabrera3
1National Autonomous University of Mexico,2National Polytechnic Institute,3EMBL-EBI

Analysis of putative biomarkers of resistance to retinoids in neuroblastoma cells and tumor tissue samples

Year:

Session type:

Theme:

Viera Dobrotkova1,Petr Chlapek1,Katerina Adamkova2,Marta Jezova3,Pavel Mazanek3,Jaroslav Sterba3,Renata Veselska4
1Masaryk University, International Clinical Research Center, St. Anne’s University Hospital Brno,2Masaryk University,3University Hospital Brno, Masaryk University,4Masaryk University, International Clinical Research Center, St. Anne’s University Hospital Brno, University Hospital Brno, Masaryk University

Acid ceramidase expression and poor neoadjuvant responses in rectal cancer – is the modulation of apoptosis a key mechanism?

Year:

Session type:

Theme:

Narendranath Govindarajah1,Rachael Clifford1,Paul Sutton1,David Bowden1,Dale Vimalachandran2,Jason L Parsons1
1University of Liverpool,2The Countess of Chester Hospital

Proteomic analysis of colorectal cancer cell resistance to 5-fluorouarcil and oxaliplatin reveals new mechanisms, prognostics markers and options for novel second line therapy

Year:

Session type:

Theme:

Nadezda Dreize1,Algirdas Kaupinis1,Marija Ger1,Jonas Cicenas1,Arvydas Laurinavicius2,Mindaugas Valius1
1Proteomics Center, Institute of Biochemistry, Vilnius University Life Sciences Center, Vilnius,2National Center of Pathology, Affiliate of Vilnius University Hospital Santara Clinics, Vilnius

Comparing Continuous Hyperfractionated Accelerated Radiotherapy (CHART) and hypofractionated radiotherapy in non-small cell lung cancer – a retrospective study

Year:

Session type:

Theme:

Wai-Yan Poon1,Philip McLoone1,Yvonne Flanagan1,David Keiller1,Suzanne Currie1,Stephen Harrow1
1Beatson West of Scotland Cancer Centre

A national snapshot of real-world combination checkpoint inhibitor induced immune-related colitis

Year:

Session type:

Theme:

Anna Olsson-Brown1,S Subramanian2,C Connell3,P Corrie3,N Steven4,J Sacco1
1The Clatterbridge Cancer Centre NHS Foundation Trust and University of Liverpool,2The Royal and Broadgreen University Hospitals NHS Trust,3Cambridge University Hospitals NHS Foundation Trust,4Birmingham University Hospitals NHS Trust

Exploring the mechanism of action of a novel ent-kaurene diterpenoid for the treatment of colon cancer

Year:

Session type:

Theme:

Md. Shahid Sarwar1,Yixuan Xia1,Ku Chuen Fai1,Siu Wai Tsang1,Man Shing Wong1,Hong-Jie Zhang1
1Hong Kong Baptist University

A Single Centre Study to Assess Outcomes and Toxicity Profiles in Patients with Non-Small Cell Lung Cancer Receiving Pembrolizumab Therapy

Year:

Session type:

Theme:

Wing Kin Liu1,Stephen Robinson1,David Chao2
1North Middlesex Hospital,2Royal Free Hospital

CORINTH: A Phase 1b/II trial of Checkpoint Inhibitor (Pembrolizumab an anti PD-1 antibody) plus standard Chemoradiotherapy (CRT) in stage III Squamous Cell carcinoma (SCC) of the anus

Year:

Session type:

Theme:

Martina Svobodova1,Marcia Hall2,Richard Adams1,Rob Glynne-Jones2,Sheela Rao3,Marianne Grønlie Guren4,Alexandra Gilbert5,Morny Drury6,Natalie Abbott7,Samuel Bosompem8,Lisette Nixon1,Charlotte Wilhelm-Benartzi1,Duncan Gilbert9,Vicky Goh10
1Centre for Trials Research, Cardiff University,2Mount Vernon Cancer Centre,3Royal Marsden Hospital,4Oslo University Hospital,5University of Leeds,6Patient Representative, Centre for Trials Research,7RTTQA, Velinder Cancer Centre,8London School of Hygiene and Tropical Medicine,9Royal Sussex County Hospital,10King's College London

Pimozide: An antipsychotic drug suppresses brain tumor growth by targeting STAT3 signaling.

Year:

Session type:

Theme:

Itishree Kaushik1,Alok Ranjan2,Blake Schwettmann3,Sanjay Srivastava4
1Texas tech university health sciences center,2NIH Clinical Center (CC),3not known,4Texas Tech University Health Sciences Center

Discovery of anti-cancer effects of Pimavanserin tartrate in Pancreatic cancer

Year:

Session type:

Theme:

Sharavan Ramachandran1,Sanjay Srivastava1
1Texas Tech University Health Sciences Center

Safety of outpatient management of cancer patients at risk of neutropenic sepsis using MASCC score at the Norfolk and Norwich University Hospital

Year:

Session type:

Theme:

Ahmed Eltinay1,Gill Gray1,Ricky Fenn1,Saif Ahmad1
1Norfolk and Norwich University Hospital

Disulfiram reverses chemoresistance in pancreatic ductal adenocarcinoma (PDAC) by targeting hypoxia induced NF-KB pathway to eradicate cancer stem cell population

Year:

Session type:

Theme:

Ogechi Nkeonye1,Ogechi Nkeonye1,Vinodh Kannappan1,Rajagopal Kilari1,Kate Butcher1,Karim Azar1,Mark Morris1,Christopher Heeschen2,Weiguang Wang1
1University of Wolverhampton,2Barts Cancer Institute

Ensartinib inhibits ABC drug efflux transporters and biotransformation enzymes and modulates pharmacokinetic multidrug resistance in vitro

Year:

Session type:

Theme:

Dimitrios Vagiannis1,Martin Svoren1,Frantisek Staud1,Martina Ceckova1,Jakub Hofman1
1Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology

The use of pertuzumab for breast cancer patients in the neo-adjuvant setting presenting to a tertiary centre

Year:

Session type:

Theme:

Gurvin Chander1,Daniel Rea1,Abeer Shaaban1,Mariam Jafri1
1University Hospitals Birmingham

Development of nano-enabled disulfiram reverses pan-chemoresistance by inhibiting hypoxia induced cancer stem cells in non-small cell lung cancer

Year:

Session type:

Theme:

Kate Butcher1,Vinodh Kannappan2,Karim Azar2,Rajagopal Kilari2,Mark R Morris2,Christopher McConville3,Yaohe Wang4,Weiguang Wang2,Sathishkumar Kurusamy2
1Research Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton,2University of Wolverhampton,3University of Birmingham,4Queen Mary University of London

Patient recall of breast radiotherapy toxicities

Year:

Session type:

Theme:

Alison Stillie1,Justin Geddes2,Hanlin Wong2,Kayla Duverger3,Ciaran Gunn2,Elizabeth Drinkwater2,Beth McConnell2,Samuel Fowler2
1NHS Lothian,2University of Edinburgh Medical School,3University of edinburgh

Feasibility and outcomes of craniospinal irradiation and concurrent daily carboplatin chemotherapy in children and adults with high risk CNS embryonal tumours, pineoblastoma and metastatic ependymoma

Year:

Session type:

Theme:

Ramsay Singer1,Liam Welsh2,Fernando Carceller2,Sucheta Vaidya2,Joanna Stone2,Rupal Evans2,Ann Petruckevitch2,Ben O’Leary3,Stergios Zacharoulis2,Frank Saran2,Henry Mandeville2
1The Institute of Cancer Research,2The Royal Marsden Hospital, Sutton,3The Institute of Cancer Research, London

T-oligo mediates DNA damage responses by modulating telomere associated proteins and telomerase

Year:

Session type:

Theme:

Zachary Schrank1,Nabiha Khan1,Joseph Kellen1,Sanjana Singh1,Chike Osude1,Neelu Puri1
1UIC College of Medicine Rockford

Long term aspirin treatment alters radiation sensitivity in colorectal cancer

Year:

Session type:

Theme:

Eleanor Mortensson1,Adam Chambers2,Katherine Gash3,Rhys Morgan4,Michael Thomas3,Ann Williams1
1University of Bristol,2,3University Hospitals Bristol NHS Foundation Trust,4University of Sussex

Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug

Year:

Session type:

Theme:

Marco Velasco-Velazquez1,Luz Vásquez-Bochm1,Mireya Velázquez-Paniagua1,Sandra Castro-Vázquez1,Sandra Guerrero-Rodríguez1,Abimael Mondragon-Peralta1,Mayra Pérez-Tapia2,Aliesha González-Arenas1
1National Autonomous University of Mexico,2National Polytechnic Institute

ICEC0942, a new oral selective inhibitor of the cell cycle and transcriptional regulator CDK7 for the treatment of breast and other cancers

Year:

Session type:

Theme:

Simak Ali1
1Imperial College London

A systematic review of eligibility criteria for phase II clinical trials for patients with lung cancer

Year:

Session type:

Theme:

Gary Doherty1,Innocent Ogunmwonyi2,Rohan Shotton1
1Cambridge University Hospitals NHS Foundation Trust,2University of Cambridge

Glyoxalase 1 expression, copy number and survival analysis in clinical treatment of breast cancer

Year:

Session type:

Theme:

Muhanad Alhujaily1,Mingzhan Xue1,Naila Rabbani1,Paul Thornalley1
1University of Warwick

High-dose chemotherapy (HDCT) in relapsed or refractory metastatic germ cell cancer: the Scotland experience.

Year:

Session type:

Theme:

Yun Yi Tan1,Bahaa Al-Bubseeree1,David Irvine2,Graham MacDonald3,Grant McQuaker2,Anne Parker2,Ashita Waterston1,Jeff White1
1Beatson West of Scotland Cancer Centre,2Queen Elizabeth University Hospital, NHS GGC,3Aberdeen Royal Infirmary, NHS Grampian

Liver-directed therapy for hepatic metastases- surgical vs. radiological management

Year:

Session type:

Theme:

Lennard YW Lee1,Adetokunbo Fadipe2,Rachel Kerr3
1Institute of Cancer Sciences, Universityof Birmingham,2Oxford University Medical School,3Oxford University Hospital NHS Trust

Renal function assessment in head and neck cancer patients receiving chemotherapy: An audit of local practice.

Year:

Session type:

Theme:

Anna Anosova1,Nida Pasha1,Suzanne Douglas2,Kevin Chiu1,Catherine Lemon1,Kee Howe Wong1
1Mount Vernon Cancer Centre,2Mount Vernon Cancer Centre Nuclear Medicine Department

Next generation of antibody conjugates formats for the cancer therapy

Year:

Session type:

Theme:

Wen-hui Liu1,Wen-bin Zhao1,Shu-qing Chen1,Zhan Zhou1
1Zhejiang University

Assessing the risk of chemotherapy toxicity and hospital admission due to toxicity

Year:

Session type:

Theme:

Samuel Malton1
1Nottingham University Hospitals

A retrospective audit to evaluate the impact on overall survival in melanoma patients treated with pembrolizumab [Keytruda], who have received a dose banded dose versus patient specific dose.

Year:

Session type:

Theme:

Aisha Farooq1
1The Christie

A retrospective review of colorectal cancer (CRC) liver resections in Greater Manchester. Looking for new clinical predictive markers beyond margin status.

Year:

Session type:

Theme:

Theodora Germetaki1,Magdy Nasralla2,Saurabh Jamdar3,Misra Vivek4,Saifee Mullamitha2,Thomas Satyadas3,Nooreen Alam4,Rahul Deshpande5,Francisca E. Marti Marti2,Nicola De Liguori-Carino3,Jurjees Hasan2,Aali Sheen3,Gregory Wilson2,Ganesh Radakrishna6,Ajith Siriwardena3,Andrew Renehan7,Michael Braun2,Mark Sunders4,Derek O'Reilly3,Jorge Barriuso8
1The Christie NHS Foundation trust,2Department of Medical Oncology, The Christie NHS Foundation Trust,3Hepato-Pancreato-Biliary Unit, Manchester University NHS Foundation Trust,4Department of Clinical Oncology, The Christie NHS Foundation Trust,53.Hepato-Pancreato-Biliary Unit, Manchester University NHS Foundation Trust,6Department of Clinical Oncology, The Christie NHS Foundation Trus,7Division of Cancer Sciences / The Christie NHS Foundation Trust, University of Manchester,8Division of Cancer Sciences / The Christie NHS Foundation Trust

BCL-3 expression is an important determinant of the DNA damage response in colorectal cancer

Year:

Session type:

Theme:

Adam Chambers1,Chris Parker2,Eleanor Mortensson2,Alice Sherrard2,Kat Gash2,Ann Williams2
1,2University of Bristol

Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC)

Year:

Session type:

Theme:

Mark Saunders1,Antoine Hollebecque2,Aitana Calvo3,Thierry André4,Guilem Argiles5,Andres Cervantes6,Catherine Leger7,Aude Valette7,Nadia Amellal7,Ronan Fougeray7,Josep Tabernero5
1The Christie NHS Foundation Trust, Manchester,2Drug Development Department (DITEP: Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer campus, Villejuif,3Gregorio Marañon University General Hospital, Madrid,4Hôpital Saint-Antoine, service d'oncologie, 184, rue du Faubourg-Saint-Antoine, Paris,5Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona,6Department of Medical Oncology, Biomedical Research Institute, Incliva, University of Valencia,7Institut de Recherches Internationales Servier, Suresnes

The CamGFR model for renal function in patients with cancer: Validation and extension for use with data from isotope mass dilution spectrometry creatinine assays

Year:

Session type:

Theme:

Edward Williams1,Cameron Whitley1,Jamie Weaver2,Claire Connell1,Reed Stratton Geisler1,Daniel Giglio3,Simon Tavaré1,Duncan Jodrell1,Tobias Janowitz1
1Cancer Research UK Cambridge Institute, Cambridge,2Christie NHS Foundation Trust, Mancherster,3University of Gothenburg, Gothenburg

Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476)

Year:

Session type:

Theme:

Christopher C Parker1,Christopher C Parker1,Nicholas D James2,Chris Brawley3,Noel W Clarke4,Gerhardt Attard5,Simon Chowdhury6,Bill Cross7,Clare Gilson3,Robert J Jones8,Robin Millman9,David P Dearnaley10,Malcolm D Mason11,Alastair Ritchie9,J Martin Russell12,Syed Adnan Ali13,Chinnamani Eswar14,Joanna Gale15,Alex Hoyle13,Jason Lester16,Denise Sheehan17,Anna Tran13,Silke Gillessen18,Claire Amos3,Mahesh KB Parmar3,Matthew R Sydes3
1Institute of Cancer Research, Sutton; Royal Marsden Hospital, Sutton,2Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham,3MRC Clinical Trials Unit at UCL,4Christie and Royal Salford Hospital, Manchester,5UCL Cancer Institute,6Guy's and St Thomas' NHS Foundation Trust,7St James University Hospital,8Institute of Cancer Sciences, University of Glasgow, Glasgow; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow,9c/o MRC Clinical Trials Unit at UCL,10Institute of Cancer Research, Sutton,11University of Cardiff,12Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre, University of Glasgow, UK,13Christie Hospital,14Royal Liverpool University Hospital,15Queen Alexandra Hospital,16Weston Park Hospital,17Royal Devon and Exeter NHS Foundation Trust,18Division of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen

Does Pharmacological Inhibition of Acid Ceramidase Improve Radiosensitivity for Locally Advanced Rectal Cancer?

Year:

Session type:

Theme:

Rachael Clifford1,Naren Govindarajah1,David Bowden1,Paul Sutton1,Jason Parsons1,Dale Vimalachandran2
1Institute of Cancer Medicine, The University of Liverpool,2The Countess of Chester Hospital NHS Foundation Trust

Optimising Chimeric Antigen Receptors (CARs) Targeting Anaplastic Lymphoma Kinase (ALK) for Childhood Cancer Immunotherapy

Year:

Session type:

Theme:

Emma Halliwell1,Jenny Yeung2,Artemis Gavrill2,Tom Pataillot-Meakin3,Maria Alonso-Ferrary4,Karin Straathof1,Martin Pule5,Kerry Chester5,Enrique Miranda Rota5,John Anderson1,Talia Gileadi6
1UCL ICH,2ICH UCL,3UCL department of infection and immunity,4GSK,5UCL Cancer Institute,6UCL

RhoB as a novel molecular target for chemotherapy of colorectal cancer

Year:

Session type:

Theme:

Maria Kopsida1
1Linkoping University

Malignant Spinal Cord Compression (MSCC) – How can we do better?

Year:

Session type:

Theme:

Sarah Slater1,Saurabh Vohra1,Robert Rulach1,Carrie Featherstone1,Derek Grose1,Cathy Hutchison1
1Beatson West of Scotland Cancer Centre

DETERMINATION OF THE EFFECTS OF DOXORUBICIN UPON CELLULAR GROWTH AND DNA INTEGRITY IN VARIOUS CELL LINES

Year:

Session type:

Theme:

Nageshwar Rao1
1Mamata Medical College, Khammam, Telangana

Patient expectations of breast clinical oncology new patient consultation

Year:

Session type:

Theme:

Alison Stillie1,Stephanie Pennycook2
1NHS Lothian,2University of Edinburgh Medical School

Clinical trial methodology in evaluating the benefits of proton beam therapy: a systematic review

Year:

Session type:

Theme:

Mercy Ofuya1,Lucy McParland2,Sarah Brown2,Louise Murray2,David Sebag-Montefiore2,Emma Hall1
1Institute of Cancer Research,2University of Leeds

Safety and efficacy of moderately hypo-fractionated radiotherapy regimen for central non-small cell lung cancer (NSCLC): Leeds Cancer Centre Experience.

Year:

Session type:

Theme:

Tanzeel Janjua1
1St. James's Hospital leeds, UK

12 week PET-CT scans post-radiotherapy for Human Papillomavirus (HPV) positive Oropharygeal Squamous Cell Cancers (OPSCC) have low positive predictive value (PPV) for lymph node (LN) residual disease

Year:

Session type:

Theme:

Robert Rulach1,Suyun Zhou1,Fraser Hendry2,David Stobo2,Mary Frances Dempsey2,Derek Grose1,Carolynn Lamb1,Allan James1,Stefano Schipani1,Christina Wilson1,Mohammed Rizwanullah1,Claire Paterson1
1The Beatson West of Scotland Cancer Centre,2NHS Greater Glasgow and Clyde

Glyoxalase 1 overexpression associated multidrug resistance in cancer chemotherapy

Year:

Session type:

Theme:

Hafsa Abbas1,Dr Mingzhan Xue1,Dr Naila Rabbani1,Professor Paul Thornalley1
1University of Warwick

MiST3: A phase II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in patients with malignant mesothelioma

Year:

Session type:

Theme:

Matthew Krebs1,Louise Carter1,Shaun Villa1,Emma Darlington1,Amy King2,Clare Massey3,James Lorens3,Dean Fennell2
1The Christie NHS Foundation Trust,2University of Leicester and Leicester University Hospitals,3BerGenBio

ATHENA (GOG-3020/ENGOT-ov45): a randomised, double-blind, placebo-controlled, phase 3 study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer

Year:

Session type:

Theme:

Rebecca S. Kristeleit1,Iain A. McNeish2,Roshan Agarwal3,Susana Banerjee4,Clare Barlow5,Michelle Ferguson6,Maxine Flubacher7,Marcia Hall8,Rebecca Herbertson9,Jane Hook10,Rachel Jones11,Louise Li12,Fiona Lofts13,Rowan E. Miller14,Sarah Moon15,Shibani Nicum16,Fiona Nussey17,Christine Parkinson18,Justin Waters19,Isabella Capobianco20,Sandra Goble20,Nikolay Grechko20,Bradley J. Monk21
1University College London Cancer Institute, UCL,2Imperial College London,3Northampton General Hospital,4The Royal Marsden NHS Foundation Trust,5Musgrove Park Hospital,6Ninewells Hospital & Medical School,7Poole Hospital NHS Foundation Trust,8Mount Vernon Cancer Centre,9Royal Sussex County Hospital,10St James’s University Hospital,11South West Wales Cancer Centre,12The James Cook University Hospital,13St George’s Hospital,14St. Bartholomew's Hospital, Barts Health NHS Trust,15Morecombe Bay NHS Trust, Lancaster,16Oxford Cancer Centre,17Edinburgh Cancer Centre, Western General Hospital,18Addenbrookes Hospital, Cambridge,19East Kent Hospitals University NHS Foundation Trust,20Clovis Oncology, Inc.,21Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine

Primary concurrent chemoradiotherapy for locally advanced laryngeal squamous cell carcinoma

Year:

Session type:

Theme:

Delali Adjogatse1,Francesca De Felice2,Yae-eun Suh3,Jean-Pierre Jeannon4,Richard Oakley4,Ricard Simo4,Mary Lei5,Teresa Guerrero Urbano5
1Guy's and St Thomas' NHS Foundation Trust,2Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome,3Department of Clinical Oncology, Royal Marsden Hospitals NHS Foundation Trust, London,4Head and Neck Unit, Guy's and St Thomas' NHS Foundation Trust, London,5Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, London